Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 84 | ETA2022 | Next issue

44th Annual Meeting of the European Thyroid Association (ETA) 2022

Brussels, Belgium
10 Sep 2022 - 13 Sep 2022

Card image cap

Poster Presentations

Graves’ Disease 2 and Orbitopathy

ea0084ps3-12-106 | Graves’ Disease 2 and Orbitopathy | ETA2022

Alterations in the gut microbiota are associated with the humoral immune response in graves’ disease

Liu Yalei

Background: Graves’ disease (GD) is characterized by lymphocytic infiltration and autoimmune activation. The gut microbiota plays a pivotal role in immune regulation. The underlying mechanism of the gut microbiota in GD autoimmunity remains elusive. The present study aimed to investigate the role of the gut microbiota in the humoral immunity of GD.Methods: A total of 45 healthy controls (HCs) and 68 GD patients [52 without treatment (U_GD) and 16 wi...

ea0084ps3-12-107 | Graves’ Disease 2 and Orbitopathy | ETA2022

Macrophage-orbital fibroblasts interaction in context of hypoxic signaling for inflammatory processes during graves’ orbitopathy

Gortz Gina-Eva , Eckstein Anja , Jesenek Christoph , Horstmann Mareike , Philipp Svenja , Bruderek Kirsten , Oeverhaus Michael , Daser Anke , Bechrakis Nikolaos , Brandau Sven , Berchner-Pfannschmidt Utta

Introduction: The inflammatory eye disease Graves’ orbitopathy (GO) is the main complication of Graves’ disease in patients. In previous studies we have shown that hypoxia and HIF-1 dependent pathways could play an important role in the pathogenic process of GO. Hypoxia is known to attract inflammatory cells and therefore maintains inflammation and recruitment of immune cells like macrophages (MQ). However, few is known about the specific contribution of MQ to the pr...

ea0084ps3-12-108 | Graves’ Disease 2 and Orbitopathy | ETA2022

The incidence and risk factors of radioiodine-induced graves’ disease following treatment of thyroid autonomous tissue

Zaletel Tjaša , Rot Živa , Krkovic Danijela , Gaberscek Simona , Zaletel Katja

Introduction: Radioiodine (I-131) therapy is an effective treatment for thyroid autonomy but may induce Graves’ disease (GD) but in up to 5% of patients. GD is characterised by antibodies against TSH receptor (TSHRAb). We set out to evaluate the incidence and risk factors of I-131-induced GD in patients with thyroid autonomy treated with I-131.Methods: We retrospectively reviewed patients with solitary toxic adenoma or toxic nodular goiter who were ...

ea0084ps3-12-109 | Graves’ Disease 2 and Orbitopathy | ETA2022

Blocking the TSH receptor with human monoclonal autoantibody K1-70TM in patients with graves’ disease – results from a phase 1 clinical trial

Furmaniak Jadwiga , Sanders Jane , Sanders Paul , Li Yang , Rees Smith Bernard

Objectives: TSH receptor (TSHR) autoantibodies (TRAb) which mimic the actions of TSH are responsible for hyperthyroidism in Graves’ disease (GD) which is often associated with Graves’ orbitopathy (GO). K1-70 is a TSHR specific human monoclonal autoantibody which binds to the TSHR with high affinity and prevents stimulation of the TSHR by TSH and TRAb. Safety, tolerability, pharmacokinetic, pharmocodynamic and immunogenic effects of K1-70 in patients with GD were asse...

ea0084ps3-12-110 | Graves’ Disease 2 and Orbitopathy | ETA2022

Linear mixed model analysis of quality of life scores in patients with thyroid eye disease treated with teprotumumab from three 24-week clinical trials

Kahaly George , Qashqai Anahita , Barretto Naina , Vesel Claudia , Holt Robert

Objectives: Teprotumumab, an IGF1-receptor antagonist, has been shown in three clinical trials to markedly improve the clinical course of Thyroid Eye Disease (TED) or Graves’ Orbitopathy (GO) with significant improvements noted in inflammation, proptosis, and diplopia. Furthermore, compared to placebo moderate-to-large improvements were noted in the total, appearance (AP), and visual function (VF) as measured by EUGOGO GO quality of life (GO-QOL) scores after 24 weeks of ...

ea0084ps3-12-111 | Graves’ Disease 2 and Orbitopathy | ETA2022

Circulating marginal zone b cells and IGA serum levels as potential biomarkers of clinical activity of graves’ orbitopathy

Stojkovic Mirjana , Perovic Vladimir , Ciric Jasmina , Beleslin Biljana , Janic Tamara , Popadic Dusan , Zarkovic Milos

Objectives: The Clinical Activity Score (CAS) is used to measure and classify Graves orbitopathy activity (GO). However, CAS is partly subjective, and the evaluation of its components is binary. As CAS is known to be correlated with TSH receptor antibodies (TRAb), we wanted to evaluate other immunological parameters in the peripheral blood as markers of GO activity.Methods: The study included 32 patients (19 females, 13 males). CAS was evaluated by a sin...

ea0084ps3-12-112 | Graves’ Disease 2 and Orbitopathy | ETA2022

Alemtuzumab-induced graves’ orbitopathy successfully treated with a single dose of rituximab

Di Marco Francesco , Porcaro Laura , Crivicich Erica , Curro Nicola , Arosio Maura , Muller Ilaria , Salvi Mario

Introduction: The humanized antibody anti-CD52+ alemtuzumab has been approved since 2014 for the treatment of relapsing-remitting multiple sclerosis (RRMS). Immune reconstitution after alemtuzumab induces thyroid autoimmunity in 34-41% of patients with RRMS, with Graves’ disease (GD) accounting for 63-65% of cases. Graves’ Orbitopathy (GO) may also occur in 13% of patients after alemtuzumab and is scarcely reported. Here we present the first case of alemtuzumab-induc...

ea0084ps3-12-113 | Graves’ Disease 2 and Orbitopathy | ETA2022

Temporal trends in the clinical presentation of graves’ ophthalmopathy: a single – centre retrospective study

Le Moli Rosario , Naselli Adriano , Tumino Dario , Piticchio Tommaso , Vella Veonica , Belfiore Antonino , Frasca Francesco

Background: Graves’ ophthalmopathy (GO) is an autoimmune disease that affects particularly the retrobulbar soft tissues and represents the most common extrathyroidal manifestation of Graves’ disease (GD). Some studies suggest that GO in newly diagnosed patients in recent years has a trend towards a less severe clinical presentation, moreover we have no studies that focus the trend of clinical presentation of GO in the last decade on the population of our area.<p ...